Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH Common Stock Issued
Cash raised by issuing new shares.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
Common Stock Issued · Q2 FY2026 · quarter ended Jun 2026
Common stock issued turns negative
Q2 FY2026 common stock issued was -$674.28M, compared with $568K a year earlier. Trailing-twelve-month common stock issued was $64.4M.
Context
- Common stock issued amounted to 13758.6% of revenue in FY2025, up 9441.1 pp from a year earlier.
- Common stock issued increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly common stock issued holds near -$674.28M or moves back toward the trailing-twelve-month quarterly average of $16.1M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 280.13M USD
- Year-over-year change
- +4.1%
- 4-year CAGR
- +33.0%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 280.13M | +4.1% |
| FY2024 | 2024-12-31 | 269.2M | +273.9% |
| FY2023 | 2023-12-31 | 72M | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 89.6M | — |
Common Stock Issued vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's LTM Jun 2026 common stock issued of $64.4M is the 5th largest of the 10 companies compared; the peer median is $27.99M.
- Its year-over-year change of +60.1% is the 5th highest of 8, against a peer median of +86.0%.
- Common stock issued amounts to 3382.4% of revenue for DNTH, versus a peer median of 1299.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $568.16M | +18.4% | +103.7% | 8007.9% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $360.93M | +86.0% | — | 4878.8% |
| LTM Jun 2026 | $311.34M | -10.5% | +52.8% | — | |
| LTM Mar 2026 | $78.57M | +31216.6% | +2580.0% | — | |
| LTM Jun 2026 | $64.4M | +60.1% | — | 3382.4% | |
| LTM Mar 2026 | $27.99M | -72.1% | +6.4% | 12.0% | |
| LTM Mar 2026 | $15.81M | +1996.9% | — | 890.8% | |
| LTM Mar 2026 | $10.36M | — | — | 19.3% | |
| FY2025 | $1.09M | +381.5% | +293.1% | 1707.8% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $131K | — | — | — |
| Peer median (excluding DNTH) | $27.99M | +86.0% | +103.7% | 1299.3% | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.14M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| Deferred Income Tax | 0 | 0 | (661K) | 0 | 0 |
| Stock-Based Compensation | 0 | 1.52M | 2.9M | 12.89M | 22.79M |
| Change in Working Capital | (1.53M) | (1.65M) | 4.86M | (351K) | 16.73M |
| Accounts Receivables | 0 | (4.16M) | 5.16M | 0 | 755K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (720K) | 2.28M | 661K | 8.19M | 11.28M |
| Other Working Capital | (806K) | 229K | (959K) | (8.54M) | 4.69M |
| Other Non-Cash Items | 11.11M | (606K) | (762K) | (6.17M) | (6.67M) |
| Operating Cash Flow | (59.53M) | (29.07M) | (36.86M) | (78.18M) | (129.06M) |
| Capital Expenditures | (1.26M) | (139K) | (110K) | (105K) | (213K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (45.31M) | (61.68M) | (57.42M) | (413.71M) | (435.01M) |
| Sales of Investments | 90M | 2M | 77.79M | 127M | 312.39M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 43.43M | (59.82M) | 20.25M | (286.81M) | (122.83M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 89.6M | 0 | 72M | 269.2M | 280.13M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (3.32M) | 61.57M | (13.58M) | 0 |
| Financing Cash Flow | 89.6M | 96.68M | 133.57M | 255.62M | 280.13M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 73.5M | 7.79M | 116.97M | (109.37M) | 28.23M |
| Free Cash Flow | (60.8M) | (29.21M) | (36.97M) | (78.29M) | (129.27M) |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.